Calliditas Therapeutics IPO Presentation Deck

No clinically meaningful changes in blood pressure and body weight during Nefecon treatment Change from baseline in SBP (mm/Hg) Blood pressure ● No clinically meaningful changes from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) D Placebo EoT follow-up Note: Data on file. calliditas NEFECON 8 mg EOT Last follow-up NEFECON 16 mg EDT follow-up Change from baseline in DBP (mm/Hg) 8 20 Placebo 8 follow-up NEFECON 8 mg EDT follow-up NEFECON 16 mg EST follow-up Change from baseline in body weight (kg) Body weight No clinically meaningful changes from baseline in body weight 10 -10 Placebo 9 . ET Last follow-up NEFECON 8 mg EOT Last follow-up NEFECON 16 mg EOT Last follow-up June 2020 14

View entire presentation